Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo
{"title":"Top 20 <i>EGFR+</i> NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating <i>EGFR</i> Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.","authors":"Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo","doi":"10.2147/LCTT.S463429","DOIUrl":null,"url":null,"abstract":"<p><p>The year 2024 is the 20<sup>th</sup> anniversary of the discovery of activating epidermal growth factor receptor (<i>EGFR</i>) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been made in the treatment of NSCLC based on this discovery. Some of these studies have led to seismic changes in the concept of oncology research and spurred treatment advances beyond NSCLC, leading to a current true era of precision oncology for all solid tumors. We now routinely molecularly profile all tumor types and even plasma samples of patients with NSCLC for multiple actionable driver mutations, independent of patient clinical characteristics nor is profiling limited to the advanced incurable stage. We are increasingly monitoring treatment responses and detecting resistance to targeted therapy by using plasma genotyping. Furthermore, we are now profiling early-stage NSCLC for appropriate adjuvant targeted treatment leading to an eventual potential \"cure\" in early-stage <i>EGFR+</i> NSCLC which have societal implication on implementing lung cancer screening in never-smokers as most <i>EGFR+</i> NSCLC patients are never-smokers. All these advances were unfathomable in 2004 when the five papers that described \"discoveries\" of activating <i>EGFR</i> mutations (del19, L858R, exon 20 insertions, and \"uncommon\" mutations) were published. To commemorate this 20<sup>th</sup> anniversary, we assembled a global panel of thoracic medical oncology experts to select the top 20 papers (publications or congress presentation) from the 20 years since this seminal discovery with December 31, 2023 as the cutoff date for inclusion of papers to be voted on. Papers ranked 21 to 30 were considered \"honorable mention\" and also annotated. Our objective is that these 30 papers with their annotations about their impact and even all the ranked papers will serve as \"syllabus\" for the education of future thoracic oncology trainees. Finally, we mentioned potential practice-changing clinical trials to be reported. One of them, LAURA was published online on June 2, 2024 was not included in the list of papers to be voted on but will surely be highly ranked if this consensus survery is performed again on the 25<sup>th</sup> anniversay of the discovery <i>EGFR</i> mutations (i.e. top 25 papers on the 25 years since the discovery of activating <i>EGFR</i> mutations).</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"15 ","pages":"87-114"},"PeriodicalIF":5.1000,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer: Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/LCTT.S463429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The year 2024 is the 20th anniversary of the discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been made in the treatment of NSCLC based on this discovery. Some of these studies have led to seismic changes in the concept of oncology research and spurred treatment advances beyond NSCLC, leading to a current true era of precision oncology for all solid tumors. We now routinely molecularly profile all tumor types and even plasma samples of patients with NSCLC for multiple actionable driver mutations, independent of patient clinical characteristics nor is profiling limited to the advanced incurable stage. We are increasingly monitoring treatment responses and detecting resistance to targeted therapy by using plasma genotyping. Furthermore, we are now profiling early-stage NSCLC for appropriate adjuvant targeted treatment leading to an eventual potential "cure" in early-stage EGFR+ NSCLC which have societal implication on implementing lung cancer screening in never-smokers as most EGFR+ NSCLC patients are never-smokers. All these advances were unfathomable in 2004 when the five papers that described "discoveries" of activating EGFR mutations (del19, L858R, exon 20 insertions, and "uncommon" mutations) were published. To commemorate this 20th anniversary, we assembled a global panel of thoracic medical oncology experts to select the top 20 papers (publications or congress presentation) from the 20 years since this seminal discovery with December 31, 2023 as the cutoff date for inclusion of papers to be voted on. Papers ranked 21 to 30 were considered "honorable mention" and also annotated. Our objective is that these 30 papers with their annotations about their impact and even all the ranked papers will serve as "syllabus" for the education of future thoracic oncology trainees. Finally, we mentioned potential practice-changing clinical trials to be reported. One of them, LAURA was published online on June 2, 2024 was not included in the list of papers to be voted on but will surely be highly ranked if this consensus survery is performed again on the 25th anniversay of the discovery EGFR mutations (i.e. top 25 papers on the 25 years since the discovery of activating EGFR mutations).